Target intelligence / Profile preview

Telomerase RNA component (TERC) (TERC)

Target
TERC
Molecular classification
Other
01

Overview

The Telomerase RNA component (TERC), also known as hTR or hTERC, is a non-coding RNA molecule that serves as an essential structural and functional component of the human telomerase ribonucleoprotein complex. It contains a critical template sequence (3'-CAAUCC-5') that is utilized by the catalytic subunit, telomerase reverse transcriptase (TERT), to synthesize and append telomeric DNA repeats (TTAGGG) to the 3' ends of linear chromosomes. This process counteracts the progressive shortening of telomeres that occurs during DNA replication, thereby preventing cellular senescence and apoptosis. While telomerase activity is tightly repressed in most normal somatic cells, it is highly upregulated in approximately 85-90% of human cancers and neoplastic progenitor cells, conferring replicative immortality. Consequently, TERC represents a compelling therapeutic target in oncology and hematologic malignancies. Drugs like imetelstat, a first-in-class lipid-conjugated oligonucleotide, directly bind to the template region of TERC, competitively inhibiting telomerase activity and driving malignant cells into replicative crisis and cell death. Conversely, loss-of-function mutations in TERC are associated with bone marrow failure syndromes and degenerative diseases, such as dyskeratosis congenita, aplastic anemia, and idiopathic pulmonary fibrosis.

Other names
hTRhTERCTelomerase RNATelomerase RNA templateTERTRTRC3DKCA1PFBMFT2SCARNA19
02

Mechanism of action

Imetelstat is a lipid-conjugated oligonucleotide that competitively binds to the template region of the telomerase RNA component (TERC/hTR). This binding prevents the hybridization of telomeric DNA and inhibits the enzymatic activity of the telomerase complex, leading to progressive telomere shortening, cellular senescence, and apoptosis in telomerase-dependent cells.

03

Biological functions

Cell cycleCell proliferationCell deathOther
04

Disease associations

CancerOther
05

Safety considerations

ThrombocytopeniaNeutropeniaHematological toxicityHepatotoxicityMyelosuppressionFatigueIncreased liver enzymes (AST/ALT)
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

Telomerase activityTelomere lengthhTERT expressionhTERC expressionCD71+ erythroid cellsBone marrow clonal burden

Beyond the preview

Go deeper on Telomerase RNA component (TERC) (TERC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telomerase RNA component (TERC) (TERC).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call